Xtx Topco LTD Sage Therapeutics, Inc. Transaction History

Xtx Topco LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$10.58 - $17.9 $510,474 - $863,657	48,249 New	48,249 $523,000
Q3 2023 Nov 13, 2023	BUY	$16.75 - $48.98 $523,571 - $1.53 Million	31,258 Added 457.32%	38,093 $783,000
Q2 2023 Aug 14, 2023	BUY	$40.65 - $59.54 $75,080 - $109,970	1,847 Added 37.03%	6,835 $321,000
Q1 2023 May 12, 2023	BUY	$37.27 - $46.57 $185,902 - $232,291	4,988 New	4,988 $209,000
Q4 2021 Feb 11, 2022	SELL	$37.06 - $47.11 $222,026 - $282,236	-5,991 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$40.26 - $57.37 $9,179 - $13,080	228 Added 3.96%	5,991 $265,000
Q2 2021 Aug 12, 2021	BUY	$54.88 - $79.29 $316,273 - $456,948	5,763 New	5,763 $327,000

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $323M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

Stay updated on Xtx Topco LTD with notifications on news.